Rapid Validation of Cancer Genes in Chimeras from Engineered Mouse Models
Author Information
Author(s): Huijbers Ivo J, Krimpenfort Paul, Berns Anton, Jonkers Jos
Primary Institution: Netherlands Cancer Institute
Hypothesis
Can a new approach using chimeric genetically engineered mouse models (GEMMs) facilitate faster validation of cancer genes and drug targets?
Conclusion
The GEMM-ESC approach allows for quick and flexible validation of cancer genes and drug targets, potentially revolutionizing cancer research.
Supporting Evidence
- The GEMM-ESC approach allows for rapid cohort generation without the need for extensive breeding.
- Chimeric models can develop tumors in the context of normal tissue, mimicking human tumorigenesis.
- The study highlights the potential for improved side-by-side comparison of cancer genes due to reduced genetic background differences.
Takeaway
Scientists are creating special mice that can help them study cancer faster and better by using a new method that combines different types of cells.
Methodology
The study describes a novel approach for generating chimeric GEMMs using embryonic stem cells derived from existing cancer-prone mouse strains.
Potential Biases
Potential bias due to the reliance on specific GEMMs and the limitations of modeling tumor extrinsic factors.
Limitations
The approach may not fully replicate tumor incidence and latency of original models and requires specialized facilities for producing chimeras.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website